Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.41 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.41 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | KLK7 | P49862 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906954 | 0.89 | SMN1; SMN2 (0.59) | SMN1; SMN2LMNAIDO1L3MBTL1SYK | |
| SCHEMBL15202883 | 0.77 | SYK (0.64) | SMN1; SMN2LMNAIDO1L3MBTL1SYK | |
| SCHEMBL12196470 | 0.77 | SMN1; SMN2 (0.76) | SMN1; SMN2LMNAIDO1L3MBTL1SYK | |
| SCHEMBL6653750 | 0.76 | F2 (0.37) | SMN1; SMN2IDO1L3MBTL1SYKMAPT | |
| SCHEMBL5143803 | 0.76 | SMN1; SMN2 (0.48) | SMN1; SMN2LMNAIDO1L3MBTL1SYK | |
| SCHEMBL6749458 | 0.76 | PTGER1 (0.41) | L3MBTL1MAPTHTT | |
| SCHEMBL13174631 | 0.76 | SMN1; SMN2 (0.62) | SMN1; SMN2LMNAIDO1L3MBTL1SYK | |
| SCHEMBL15746977 | 0.76 | LMNA (0.70) | SMN1; SMN2LMNAIDO1L3MBTL1SYK | |
| SCHEMBL15613005 | 0.76 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAIDO1L3MBTL1SYK | |
| SCHEMBL3485350 | 0.75 | SMN1; SMN2 (0.66) | SMN1; SMN2LMNAIDO1L3MBTL1SYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1589029-B1 | Pyrazinone protease inhibitors | ORTHO MCNEIL PHARM INC (US) | 2010-03-17 | — | — | EP | claimed |
| EP-3089746-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | Lifesci Pharmaceuticals, Inc. (BB) | 2016-11-09 | — | — | EP | disclosed |
| WO-2015103317-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | LIFESCI PHARMACEUTICALS, INC. (BB) | 2015-07-09 | — | — | WO | disclosed |
| US-7550474-B2 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICALS RESEARCH & DEVELOPMENT, L.L.C. (US) | 2009-06-23 | — | — | US | disclosed |
| EP-1613319-B1 | SUBSTITUTED PHENYL ACETAMIDES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7402586-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1036063-B1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2006-09-21 | — | — | US | disclosed |
| US-7029654-B2 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | ORTHO-MCNEIL PHARMACEUTICALS, INC. (US) | 2006-04-18 | — | — | US | disclosed |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | JOHNSON & JOHNSON PHARMACEUTICAL RESEARCH & DEVELOPMENT, L.L.C. | 2004-12-16 | — | — | US | disclosed |
| US-6514978-B2 | Compounds such as 1-(n-(2-(amidinoaminooxy)ethyl)amino) carbonylmethyl-6-methyl-3-(phenethylamino)-pyrazinone attached to a polymer coated onto a medical device for blood collection or storage; antiagglomerants | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-02-04 | — | — | US | disclosed |
| US-6472399-B2 | ANTICOAGULANTS; MAY BE EMBEDDED IN OR PHYSICALLY LINKED TO MATERIALS USED IN MANUFACTURE OF DEVICES USED IN BLOOD COLLECTION, CIRCULATION, STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-10-29 | — | — | US | disclosed |
| US-6417161-B1 | KETONE AMINO DERIVATIVES | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-07-09 | — | — | US | disclosed |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | LU TIANBAO (US) | 2002-07-04 | — | — | US | disclosed |
| US-6350764-B2 | FOR INHIBITING LOSS OF BLOOD PLATELETS; INHIBITING FORMATION OF BLOOD PLATELET AGGREGATES, FIBRIN, THROMBUS, AND EMBOLUS; ANTICOAGULANTS EMBEDDED IN DEVICES FOR BLOOD COLLECTION, CIRCULATION, STORAGE (CATHETERS, DIALYSIS MACHINES); STENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-02-26 | — | — | US | disclosed |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | LU TIANBAO (US) | 2001-09-13 | — | — | US | disclosed |
| US-6245763-B1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| EP-1036063-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-09-20 | — | — | EP | disclosed |
| US-6037356-A | ANTICOAGULANTS; ANTIINFLAMMATORY AND ANTIARTHRITIC AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-03-14 | — | — | US | disclosed |
| WO-1999026926-A1 | HETEROARYL AMINOGUANIDINES AND ALKOXYGUANIDINES AND THEIR USE AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211719-A1 | Heteroaryl aminoguanidine and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | SMN1; SMN2 3262/4885LMNA 2305/4885IDO1 2416/4885 |
| US-20010021713-A1 | Thromboresistant materials incorporating pyrazinone protease inhibitors | HPN, SERPINE1, SERPINC1 | SMN1; SMN2 3929/4885LMNA 1057/4885IDO1 3210/4885 |
| US-20020086872-A1 | Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors | F9, PLG, MMP9 | SMN1; SMN2 3558/4885LMNA 1902/4885IDO1 1377/4885 |
| US-20040254166-A1 | Substituted phenyl acetamides and their use as protease inhibitors | TFPI, F12, SPINT2 | SMN1; SMN2 2931/4885LMNA 2775/4885IDO1 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.